All Posts Tagged With: "BMY"
(ABT) Earnings Season in Full Swing – Earnings Preview
Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The...
24Jan2012 | vitalstocks | 0 comments | Continued(ILMN) Two Major Biotech Trends In 2012
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood...
19Jan2012 | InvestmentU | 0 comments | Continued(DUK) 2012 Predictions for Income Investors
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, December 28, 2011: Issue #1674 Last week, I reviewed my brilliant (and a few, let’s call them sub-brilliant) market calls for 2011. As the year winds down, here are my thoughts for what lies ahead in 2012 for income...
9Jan2012 | InvestmentU | 0 comments | Continued(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld
by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate...
9Jan2012 | InvestmentU | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have taken place in the pharma sector over the last couple of years. With most...
9Jan2012 | vitalstocks | 0 comments | Continued(BMY) Company News for January 04, 2012 – Corporate Summary
• Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum Exploration & Production, a unit of China Petroleum...
8Jan2012 | vitalstocks | 0 comments | Continued(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Sees Pipeline Setback
Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a combination therapy in liver cancer patients who had either failed or...
24Dec2011 | vitalstocks | 0 comments | Continued(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld
by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate...
21Dec2011 | InvestmentU | 0 comments | Continued(AZN) AstraZeneca Drug Cleared by the European Commission
AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for...
8Dec2011 | vitalstocks | 0 comments | Continued(EU) Emerging Markets: The Way Forward
According to Irish orator, philosopher, & politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. —...
7Dec2011 | vitalstocks | 0 comments | Continued(JNJ) Spotlight on Hepatitis-C Market
Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies...
7Dec2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Earns FDA Approval
Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food & Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and...
5Dec2011 | vitalstocks | 0 comments | Continued(GILD) Gilead’s Eviplera Drug is Cleared by European Medicines Agency
Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed...
30Nov2011 | vitalstocks | 0 comments | Continued(EU) Pharmaceuticals Stock Outlook – September 2011 – Industry Outlook
The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance...
23Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Presents HCV Data
Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV)....
20Sep2011 | vitalstocks | 0 comments | Continued(AZN) AstraZeneca’s Brilinta Now in US
AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following...
15Sep2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data
Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional...
14Sep2011 | vitalstocks | 0 comments | Continued(SCR) Simcere Drug Cleared in China
Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first...
1Sep2011 | vitalstocks | 0 comments | Continued(ALL) Company News for August 30, 2011 – Corporate Summary
• Bank of America (NYSE:BAC) shares increased 8.12% to close at $8.39 after the bank disclosed it would be selling half of its holdings to China Construction Bank Corp in order to raise capital • Share prices of insurer The Allstate Corp. (NYSE:ALL) advanced 8.50%...
30Aug2011 | vitalstocks | 0 comments | Continued(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts...
18Aug2011 | InvestmentU | 0 comments | Continued(ONXX) Onyx Analyst Downgrades Shares to Underperform
We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved...
16Aug2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Reports Solid Quarter
Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including...
3Aug2011 | vitalstocks | 0 comments | Continued(GILD) Gilead Sciences Earnings Grow With HIV Franchise
Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny...
3Aug2011 | vitalstocks | 0 comments | Continued(MYL) Mylan Gets HIV Rights from Gilead
Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access...
14Jul2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Presents Encouraging Data
Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32). ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole). ...
1Jul2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Expands HIV Drug’s Reach
Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart...
30Jun2011 | vitalstocks | 0 comments | Continued(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion
Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology product, Vectibix. Amgen is looking to gain EU approval for the use...
29Jun2011 | vitalstocks | 0 comments | Continued(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies
Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two...
29Jun2011 | vitalstocks | 0 comments | Continued(API) Roche Holdings Partners with Evotec
Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover protein-phosphorylations, which will help in predicting favorable dosage and efficacy...
29Jun2011 | vitalstocks | 0 comments | Continued